tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

KZIA Stock Latest News

Kazia Therapeutics Sells Cantrixil IP Rights to Vivesto for $1 Million
Company AnnouncementsKazia Therapeutics Sells Cantrixil IP Rights to Vivesto for $1 Million
11d ago
6K
KZIA
Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
PremiumThe Fly
Kazia Therapeutics sells IP, trademarks rights to Cantrixil for $1M
11d ago
KZIA
Kazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results
PremiumCompany Announcements
Kazia Therapeutics Advances Cancer Drug Development with Strategic Moves and Promising Trial Results
29d ago
6K
KZIA
Kazia Therapeutics: Buy Rating Driven by Dual Potential in GBM and Parkinson’s Disease
PremiumRatings
Kazia Therapeutics: Buy Rating Driven by Dual Potential in GBM and Parkinson’s Disease
2M ago
KZIA
Kazia Therapeutics Awarded Research Grant to Explore Paxalisib’s Potential for Parkinson’s Treatment
PremiumCompany Announcements
Kazia Therapeutics Awarded Research Grant to Explore Paxalisib’s Potential for Parkinson’s Treatment
2M ago
6K
KZIA
Kazia Therapeutics announces research grant awarded from MJFF
PremiumThe FlyKazia Therapeutics announces research grant awarded from MJFF
2M ago
KZIA
Maxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study data
Premium
The Fly
Maxim starts Kazia Therapeutics at Buy amid ‘positive’ GBM study data
2M ago
KZIA
Kazia Therapeutics initiated with a Buy at Maxim
Premium
The Fly
Kazia Therapeutics initiated with a Buy at Maxim
2M ago
KZIA
Kazia Therapeutics Highlights Ongoing Oncology Drug Development Progress
PremiumCompany Announcements
Kazia Therapeutics Highlights Ongoing Oncology Drug Development Progress
2M ago
6K
KZIA
Kazia Therapeutics Launches Innovative Breast Cancer Trial with Paxalisib and Immunotherapy
PremiumCompany Announcements
Kazia Therapeutics Launches Innovative Breast Cancer Trial with Paxalisib and Immunotherapy
2M ago
6K
KZIA
Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
PremiumThe Fly
Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
2M ago
KZIA
Kazia Therapeutics Issues Prefunded Warrant for ADS Purchase
PremiumCompany Announcements
Kazia Therapeutics Issues Prefunded Warrant for ADS Purchase
3M ago
6K
KZIA
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
PremiumThe FlyKazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering
3M ago
KZIA
Kazia Therapeutics Charts Path Forward for Paxalisib After FDA Feedback
Premium
Company Announcements
Kazia Therapeutics Charts Path Forward for Paxalisib After FDA Feedback
3M ago
6K
KZIA
Kazia announces FDA says OS data supports standard, not accelerated approval
Premium
The Fly
Kazia announces FDA says OS data supports standard, not accelerated approval
3M ago
KZIA
Kazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer Treatment
PremiumCompany Announcements
Kazia Therapeutics Presents Promising Data on Paxalisib for Breast Cancer Treatment
4M ago
6K
KZIA
Kazia Therapeutics Secures Nasdaq Compliance
PremiumCompany Announcements
Kazia Therapeutics Secures Nasdaq Compliance
5M ago
6K
KZIA
Kazia Therapeutics management to meet with Maxim
PremiumThe Fly
Kazia Therapeutics management to meet with Maxim
5M ago
KZIA
Kazia Therapeutics Advances Paxalisib with FDA Meeting
PremiumCompany Announcements
Kazia Therapeutics Advances Paxalisib with FDA Meeting
5M ago
6K
KZIA
Kazia Therapeutics announces granting of Type C meeting with FDA
PremiumThe FlyKazia Therapeutics announces granting of Type C meeting with FDA
5M ago
KZIA
Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested
Premium
Market News
Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested
6M ago
AHT
ALBT
Kazia Therapeutics trading halted, news pending
Premium
The Fly
Kazia Therapeutics trading halted, news pending
6M ago
KZIA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >